Valuation: ChitogenX Inc.

Market Cap 831K 592K 531K 490K 445K 56.22M 842K 5.88M 2.34M 29.47M 2.22M 2.17M 93.45M P/E 2023
-2.01x
P/E 2024 -3.99x
Enterprise Value 4.67M 3.33M 2.98M 2.76M 2.5M 316M 4.73M 33.04M 13.12M 166M 12.48M 12.22M 525M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
100%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0
0.12
5 years 0
Extreme 0
0.6
10 years 0
Extreme 0
1
Manager TitleAgeSince
Chief Executive Officer 65 2024-02-27
Director of Finance/CFO 62 2018-09-17
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 67 2019-03-05
Chairman 65 2016-07-25
Chairman 65 -
Date Insider Type Main position Quantity % Market Cap. Importance
11/19/24 Buy

Chief Financial Officer

710,000 0.8541%
7/17/24 Option

Chief Executive Officer

544,400 0.6549%
7/17/24 Option

General Counsel

100,000 0.1203%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-93.75% 296K
-3.10%-4.19%+32.67%+59.47% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.46%+11.00%+44.65% 32.71B
+1.11%+15.18%+60.27%+49.33% 26.5B
+1.21%-8.50%+22.96%-10.50% 24.01B
Average -0.18%-0.15%+40.90%+129.57% 38.33B
Weighted average by Cap. -0.47%-0.59%+42.37%+153.31%

Financials

2023 2024
Net sales - -
Net income -6.23M -4.44M -3.98M -3.68M -3.33M -421M -6.31M -44.07M -17.5M -221M -16.65M -16.29M -700M -1.55M -1.11M -993K -917K -831K -105M -1.57M -10.99M -4.37M -55.09M -4.15M -4.06M -175M
Net Debt 6.21M 4.42M 3.97M 3.66M 3.32M 420M 6.28M 43.9M 17.44M 220M 16.59M 16.23M 698M 3.84M 2.73M 2.45M 2.27M 2.05M 260M 3.89M 27.16M 10.79M 136M 10.26M 10.04M 432M
Projected Income Statement - Annual - ChitogenX Inc.
Logo ChitogenX Inc.
ChitogenX Inc. is a Canada-based clinical-stage regenerative medicine company. The Company is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The Company is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Employees
-

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - ChitogenX Inc.
  1. Stock Market
  2. Stocks
  3. CHGX Stock